Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,242,076
  • Shares Outstanding, K 59,598
  • Annual Sales, $ 60,000 K
  • Annual Income, $ -78,960 K
  • EBIT $ 89 M
  • EBITDA $ 88 M
  • 60-Month Beta 2.23
  • Price/Sales 7.39
  • Price/Cash Flow N/A
  • Price/Book 4.26

Options Overview Details

View History
  • Implied Volatility 89.62% ( -1.63%)
  • Historical Volatility 35.53%
  • IV Percentile 95%
  • IV Rank 82.23%
  • IV High 103.32% on 10/04/24
  • IV Low 26.27% on 06/03/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 13
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 5,946
  • Open Int (30-Day) 5,975

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.01
  • Number of Estimates 6
  • High Estimate 1.03
  • Low Estimate -0.57
  • Prior Year 0.44
  • Growth Rate Est. (year over year) -97.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.95 +1.81%
on 01/08/25
42.58 -11.65%
on 12/09/24
-4.44 (-10.56%)
since 12/06/24
3-Month
33.31 +12.94%
on 11/19/24
48.89 -23.05%
on 10/28/24
-6.34 (-14.42%)
since 10/08/24
52-Week
22.73 +65.51%
on 01/09/24
48.89 -23.05%
on 10/28/24
+14.60 (+63.42%)
since 01/08/24

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment...

PTGX : 37.62 (-2.16%)
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide...

PTGX : 37.62 (-2.16%)
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (

PTGX : 37.62 (-2.16%)
Insider Sale: Chief Medical Officer of $PTGX (PTGX) Sells 16,000 Shares

ARTURO MD MOLINA, the Chief Medical Officer of $PTGX ($PTGX), sold 16,000 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 25.6%...

PTGX : 37.62 (-2.16%)
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate...

PTGX : 37.62 (-2.16%)
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)

PTGX : 37.62 (-2.16%)
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below

PTGX : 37.62 (-2.16%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 37.62 (-2.16%)
Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Therapeutics: Q2 Earnings Snapshot

PTGX : 37.62 (-2.16%)
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal...

PTGX : 37.62 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 40.65
2nd Resistance Point 39.77
1st Resistance Point 38.70
Last Price 37.62
1st Support Level 36.75
2nd Support Level 35.87
3rd Support Level 34.80

See More

52-Week High 48.89
Fibonacci 61.8% 38.90
Last Price 37.62
Fibonacci 50% 35.81
Fibonacci 38.2% 32.72
52-Week Low 22.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar